1. Academic Validation
  2. Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2

Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2

  • J Med Chem. 2024 Feb 22;67(4):3112-3126. doi: 10.1021/acs.jmedchem.3c02287.
Joshua R Hummel 1 Kai-Jiong Xiao 1 Jeffrey C Yang 1 Leslie B Epling 1 Ken Mukai 1 Qinda Ye 1 Meizhong Xu 1 Dingquan Qian 1 Lu Huo 1 Michael Weber 1 Valerie Roman 1 Yvonne Lo 1 Katherine Drake 1 Kristine Stump 1 Maryanne Covington 1 Kanishk Kapilashrami 1 Guofeng Zhang 1 Min Ye 1 Sharon Diamond 1 Swamy Yeleswaram 1 Ricardo Macarron 1 Marc C Deller 1 Susan Wee 1 Sunkyu Kim 1 Xiaozhao Wang 1 Liangxing Wu 1 Wenqing Yao 1
Affiliations

Affiliation

  • 1 Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States.
Abstract

CDK2 is a critical regulator of the cell cycle. For a variety of human cancers, the dysregulation of CDK2/cyclin E1 can lead to tumor growth and proliferation. Historically, early efforts to develop CDK2 inhibitors with clinical applications proved unsuccessful due to challenges in achieving selectivity over off-target CDK isoforms with associated toxicity. In this report, we describe the discovery of (4-pyrazolyl)-2-aminopyrimidines as a potent class of CDK2 inhibitors that display selectivity over CDKs 1, 4, 6, 7, and 9. SAR studies led to the identification of compound 17, a kinase selective and highly potent CDK2 Inhibitor (IC50 = 0.29 nM). The evaluation of 17 in CCNE1-amplified mouse models shows the pharmacodynamic inhibition of CDK2, measured by reduced Rb phosphorylation, and antitumor activity.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-162255
    99.22%, CDK2抑制剂
    CDK